Growth Hormone 101: What it is where it comes from and what it does

Growth Hormone 101: The Complete Primer from Peter Attia

Peter Attia, a physician focused on longevity and applied science, provides one of the clearest breakdowns of growth hormone (GH) physiology available. With nearly 350,000 views, this is a reference-quality explanation of what GH actually does in the body, how its production is regulated, and why its decline with age matters. If you are going to explore GH-related peptides or therapies, understanding the basics covered here is essential context.

Growth hormone is a 191-amino-acid protein produced by somatotroph cells in the anterior pituitary gland. It is released in a pulsatile pattern throughout the day, with the largest pulses occurring during slow-wave (deep) sleep. This pulsatile pattern is important because the body responds differently to GH pulses than it does to constant GH exposure. Pulses drive the beneficial effects. Constant exposure leads to receptor desensitization and side effects.

The GH-IGF-1 Axis Explained

When GH is released from the pituitary, it travels through the bloodstream and acts on tissues throughout the body. Its single most important downstream action is stimulating the liver to produce insulin-like growth factor 1 (IGF-1). In many ways, IGF-1 is the molecule that does the actual work that people attribute to growth hormone. The GH-IGF-1 axis is the central hormonal pathway that drives growth during childhood and maintains tissue health throughout adulthood.

GH also has direct effects independent of IGF-1. It promotes lipolysis (fat breakdown) by activating hormone-sensitive lipase in fat cells. It stimulates protein synthesis directly in muscle tissue. It promotes gluconeogenesis (glucose production) in the liver, which is why excessive GH can raise blood sugar. And it supports immune function and wound healing through effects on multiple cell types.

The regulation of GH release involves a balance between two hypothalamic hormones. Growth hormone releasing hormone (GHRH) stimulates the pituitary to release GH. Somatostatin inhibits GH release. The pulsatile pattern of GH secretion results from alternating dominance of these two signals. Ghrelin, the hunger hormone produced mainly by the stomach, also stimulates GH release through a separate receptor, which is why some GH-releasing peptides target the ghrelin receptor pathway.

IGF-1, once produced, feeds back to both the hypothalamus and the pituitary to reduce GH production. This negative feedback loop keeps the system in balance. When someone takes exogenous GH, IGF-1 levels rise, which tells the pituitary to produce less of its own GH. This is why long-term exogenous GH use can suppress natural production, and why GH-releasing peptides that work through the pituitary are considered a more physiological approach.

The Decline of GH with Age

GH production peaks during puberty and then declines steadily throughout adulthood. By age 60, most people produce a fraction of the GH they did at age 20. This decline is sometimes called somatopause, by analogy with menopause and andropause. The consequences of declining GH and IGF-1 include reduced muscle mass, increased body fat (especially visceral fat), decreased bone density, thinner skin, reduced exercise capacity, and impaired immune function.

Peter Attia discusses whether this age-related GH decline is simply a natural part of aging that should be accepted or whether it represents a modifiable risk factor for age-related disease. The answer, as with most things in longevity medicine, falls somewhere in the middle. Restoring GH levels to those of a 20-year-old is probably not wise and carries real risks. But allowing GH to bottom out completely likely contributes to the functional decline and disease risk that characterize unhealthy aging.

The practical question is how to maintain GH levels in a range that supports healthy function without pushing into territory that increases cancer risk or other adverse effects. This is where the nuance of GH optimization becomes important, and where peptide-based approaches offer advantages over direct GH injection.

Natural Ways to Support GH Production

Before discussing any pharmaceutical or peptide interventions, Attia emphasizes the lifestyle factors that have the largest impact on natural GH production. Sleep is number one. The majority of your daily GH output occurs during deep sleep, and anything that impairs deep sleep (alcohol, late-night eating, blue light exposure, sleep disorders) directly reduces GH production. Fixing sleep is the highest-yield intervention for supporting GH levels naturally.

Exercise, particularly high-intensity resistance training and interval training, acutely stimulates GH release. The magnitude of the GH response depends on the intensity and volume of the exercise, with higher intensity producing larger GH pulses. Consistent training also improves the GH response to sleep over time.

Body composition matters because excess body fat, particularly visceral fat, is associated with lower GH levels. This creates a vicious cycle: low GH promotes fat accumulation, and fat accumulation further suppresses GH. Breaking this cycle through diet, exercise, and potentially targeted interventions can help restore more youthful GH dynamics.

Fasting and caloric restriction acutely increase GH release. The GH surge during fasting serves to mobilize fat for energy and preserve lean tissue, which makes evolutionary sense. Intermittent fasting protocols leverage this mechanism, though the overall impact on 24-hour GH production depends on the total eating pattern and caloric intake.

The Peptide Space for GH Optimization

Attia provides context for understanding where GH-related peptides fit in the therapeutic space. GHRH analogs (like tesamorelin, sermorelin, and CJC-1295) work by amplifying the natural GHRH signal, encouraging the pituitary to produce more GH during its normal pulsatile cycles. These are considered among the most physiological approaches because they work with the body's existing regulatory systems.

GH secretagogues (like ipamorelin and GHRP-2) work through the ghrelin receptor to trigger GH release. These can be combined with GHRH analogs for a synergistic effect that produces larger GH pulses than either approach alone.

MK-677 (ibutamoren) is an oral GH secretagogue that is popular due to its convenience (no injection required). However, it has a long half-life that produces more sustained GH elevation rather than the pulsatile pattern that the body prefers, and it can increase appetite and cause water retention. Attia is cautious about MK-677 for these reasons.

Direct GH injection remains an option but carries the most risk of side effects including joint pain, carpal tunnel syndrome, insulin resistance, and potential pituitary suppression with long-term use. It is reserved for people with diagnosed GH deficiency or specific medical indications where the benefits clearly outweigh the risks.

The Bottom Line on GH

Peter Attia's bottom line is balanced and practical. GH is an important hormone that declines with age, and this decline contributes to age-related changes that most people want to minimize. The first-line approach is optimizing the natural factors that support GH production: sleep, exercise, body composition, and meal timing. For people who have optimized these factors and still have suboptimal GH levels, peptide-based approaches offer a way to boost production while working within the body's regulatory framework. Direct GH replacement is a last resort reserved for documented deficiency or specific clinical scenarios where the risk-benefit calculation is favorable.

The Longevity Debate: Is More GH Better?

One of the most nuanced topics Attia touches on is the paradox of growth hormone in longevity research. On one hand, GH decline with age is associated with the physical deterioration that characterizes unhealthy aging. On the other hand, some of the longest-lived organisms and human populations have lower GH and IGF-1 levels than average. People with Laron syndrome, a genetic condition causing GH receptor deficiency, have very low IGF-1 levels and appear to be protected against cancer and diabetes despite their small stature.

This paradox suggests that the relationship between GH and longevity is not a simple more-is-better equation. There may be an optimal range where GH and IGF-1 levels are high enough to maintain tissue health, muscle mass, and metabolic function but not so high that they promote unchecked cell growth that could lead to cancer. Finding that range is one of the central challenges of longevity medicine.

The practical implication is that GH optimization should aim for restoration of youthful-normal levels rather than supraphysiological elevation. Using GH secretagogue peptides that work through the pituitary's natural regulatory mechanisms helps maintain this balance because the body retains the ability to modulate its own GH output through feedback loops. This built-in regulation is a significant safety advantage over direct GH injection, which bypasses these controls entirely.

Attia's measured approach to GH reflects a broader principle in longevity medicine: interventions should optimize physiology within natural parameters rather than pushing systems to extremes. The goal is not to have the GH levels of a teenager at age sixty. It is to have GH levels that support robust health, functional independence, and resilience against age-related disease at whatever age you happen to be. This nuanced perspective is what separates evidence-based longevity medicine from the hype-driven anti-aging industry, and it applies equally to GH-related peptides as it does to every other intervention in the longevity toolkit.

This foundational understanding of GH physiology is prerequisite knowledge for anyone considering GH-related peptides or therapies. Without it, you are making decisions based on marketing claims and anecdotal reports rather than an understanding of how these compounds interact with your body's hormonal regulatory systems. Attia's presentation provides exactly the kind of clear, evidence-based foundation that empowers informed decision-making and productive conversations with healthcare providers about whether GH optimization is appropriate for your individual health goals and circumstances.